TriSalus Life Sciences (TLSI) News Today $5.11 +0.22 (+4.50%) Closing price 04:00 PM EasternExtended Trading$5.22 +0.11 (+2.05%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 4,826 SharesJanuary 30 at 5:34 AM | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires $26,156.92 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary T. Szela purchased 4,826 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The shares were bought at an average price of $5.42 per share, with a total value of $26,156.92. Following the completion of the transaction, the chief executive officer now owns 429,503 shares of the company's stock, valued at $2,327,906.26. This represents a 1.14 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.January 29 at 7:19 PM | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Purchases $79,650.00 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) insider Sean Murphy purchased 15,000 shares of the stock in a transaction on Monday, January 27th. The shares were acquired at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the transaction, the insider now owns 182,732 shares of the company's stock, valued at approximately $970,306.92. The trade was a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.January 29 at 7:19 PM | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young Acquires 24,000 SharesTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CFO James Emmett Young acquired 24,000 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the transaction, the chief financial officer now directly owns 24,000 shares in the company, valued at approximately $129,600. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 29 at 7:19 PM | marketbeat.comTriSalus Life Sciences' (TLSI) Buy Rating Reiterated at Roth MkmJanuary 27 at 1:59 AM | americanbankingnews.comTriSalus Life Sciences: Strong Q4 2024 Performance and Promising 2025 Outlook Drive Buy RatingJanuary 25, 2025 | markets.businessinsider.comTriSalus Life Sciences (NASDAQ:TLSI) Earns "Buy" Rating from Roth MkmRoth Mkm restated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday.January 24, 2025 | marketbeat.comTriSalus reports 59% annual revenue growth in 2024January 23, 2025 | msn.comTriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference CallJanuary 23, 2025 | stockhouse.comTriSalus Life Sciences Prelim. Q4 Revenue SurgesJanuary 23, 2025 | markets.businessinsider.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest UpdateTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 83,800 shares, an increase of 45.5% from the December 15th total of 57,600 shares. Currently, 2.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 37,300 shares, the days-to-cover ratio is currently 2.2 days.January 16, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by BrokeragesShares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Buy" from the nine research firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and two have issued a stroJanuary 9, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in DecemberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 22.8% from the November 30th total of 46,900 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 35,900 shares, the days-to-cover ratio is presently 1.6 days.December 29, 2024 | marketbeat.comTriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are CutDecember 24, 2024 | seekingalpha.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Equity Ab Frankenius Acquires 62,972 SharesDecember 20, 2024 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in StockTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) major shareholder Equity Ab Frankenius bought 62,972 shares of the company's stock in a transaction on Tuesday, December 17th. The shares were acquired at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.December 19, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Cantor FitzgeraldCantor Fitzgerald started coverage on TriSalus Life Sciences in a research note on Tuesday. They issued an "overweight" rating and a $10.00 price objective on the stock.December 17, 2024 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by BrokeragesTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has earned a consensus rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating onDecember 15, 2024 | marketbeat.comNorthland Capmk Has Positive Outlook of TLSI FY2026 EarningsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at Northland Capmk upped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now forecasts that thNovember 28, 2024 | marketbeat.comMats Wahlstrom Acquires 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockNovember 26, 2024 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from AnalystsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has earned a consensus rating of "Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the companyNovember 20, 2024 | marketbeat.comTriSalus Life Sciences price target lowered to $11 from $12 at CanaccordNovember 16, 2024 | markets.businessinsider.comTriSalus Life Sciences: Strong Growth and Strategic Partnerships Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)November 15, 2024 | markets.businessinsider.comCanaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock PriceCanaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Friday.November 15, 2024 | marketbeat.comTriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’November 15, 2024 | markets.businessinsider.comBrokers Offer Predictions for TLSI Q3 EarningsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities researchers at Roth Capital issued their Q3 2024 earnings estimates for shares of TriSalus Life Sciences in a research report issued on Monday, November 11th. Roth Capital analyst J. Wittes forecasts that the company will post eaNovember 13, 2024 | marketbeat.comTriSalus Life Sciences initiated with a Buy at Roth MKMNovember 13, 2024 | markets.businessinsider.comRoth MKM Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationNovember 12, 2024 | msn.comTriSalus Life Sciences: Promising Growth with Innovative TriNav Catheter and TL-9 AntagonistNovember 12, 2024 | markets.businessinsider.comTriSalus Life Sciences teams with Geo-Med to expand TriNav availability to VANovember 12, 2024 | markets.businessinsider.comRoth Capital Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy"Roth Capital upgraded TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday.November 12, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Roth MkmRoth Mkm began coverage on shares of TriSalus Life Sciences in a research note on Monday. They issued a "buy" rating and a $11.00 target price for the company.November 11, 2024 | marketbeat.comTriSalus Life Sciences (TLSI) to Release Quarterly Earnings on ThursdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643229)November 7, 2024 | marketbeat.comTriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on ThursdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643229)November 7, 2024 | marketbeat.comTriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference CallOctober 31, 2024 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in OctoberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 62,100 shares, an increase of 21.3% from the September 30th total of 51,200 shares. Based on an average daily volume of 47,100 shares, the short-interest ratio is presently 1.3 days. Currently, 1.4% of the shares of the company are sold short.October 28, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Stock, Short Interest ReportOctober 26, 2024 | benzinga.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by AnalystsShares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1 yeaOctober 26, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Strong-Buy at Northland CapmkNorthland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday.October 26, 2024 | marketbeat.comNorthland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday. They set an "outperform" rating and a $12.50 target price for the company.October 25, 2024 | marketbeat.comTriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 14, 2024 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in SeptemberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 51,200 shares, a growth of 62.5% from the September 15th total of 31,500 shares. Approximately 1.0% of the company's shares are sold short. Based on an average daily volume of 46,000 shares, the days-to-cover ratio is currently 1.1 days.October 12, 2024 | marketbeat.comTriSalus Life Sciences Inc.October 10, 2024 | wsj.comTriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory BoardSeptember 26, 2024 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI)September 25, 2024 | finance.yahoo.comHighbridge Capital Management LLC Invests $1.18 Million in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 214,545 shares of the companySeptember 19, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Research Coverage Started at OppenheimerOppenheimer started coverage on TriSalus Life Sciences in a research report on Monday. They set an "outperform" rating and a $10.00 target price for the company.September 16, 2024 | marketbeat.comInsider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires 7,520 Shares of StockSeptember 14, 2024 | insidertrades.comTriSalus Life Sciences Inc (TLSI) CEO Buys SharesSeptember 14, 2024 | finance.yahoo.com Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSI Media Mentions By Week TLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSI News Sentiment▼1.020.74▲Average Medical News Sentiment TLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSI Articles This Week▼121▲TLSI Articles Average Week Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OrthoPediatrics News Today Treace Medical Concepts News Today Delcath Systems News Today ClearPoint Neuro News Today Semler Scientific News Today Nano-X Imaging News Today Tactile Systems Technology News Today NeuroPace News Today CVRx News Today ZimVie News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSI) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
